This category page covers biotechnology and pharmaceutical companies developing soluble guanylate cyclase (sGC) modulators — including sGC stimulators and sGC activators — for Alzheimer's disease and related neurodegenerative disorders. The NO-sGC-cGMP pathway represents a promising therapeutic target addressing cerebral blood flow dysfunction, oxidative stress, neuroinflammation, and protein aggregation that characterize AD pathogenesis. [@evgenov2006]
Mechanism of Action
...
Overview
Mermaid diagram (expand to render)
This category page covers biotechnology and pharmaceutical companies developing soluble guanylate cyclase (sGC) modulators — including sGC stimulators and sGC activators — for Alzheimer's disease and related neurodegenerative disorders. The NO-sGC-cGMP pathway represents a promising therapeutic target addressing cerebral blood flow dysfunction, oxidative stress, neuroinflammation, and protein aggregation that characterize AD pathogenesis. [@evgenov2006]
Mechanism of Action
sGC modulators work through the nitric oxide-soluble guanylate cyclase-cyclic guanosine monophosphate (NO-sGC-cGMP) signaling axis:
sGC Stimulators (e.g., riociguat, vericiguat): Bind to the heme moiety of sGC, stabilizing the enzyme in its active conformation and increasing cGMP production in response to NO [@stasch2011]
sGC Activators (e.g., cinaciguat): Directly activate sGC independent of NO, useful in conditions of heme oxidation or nitrosylation [@hobbs2020]
Rationale: Cerebral vascular dysfunction is an early and progressive feature of AD; improving cerebral perfusion may slow disease progression
Notes: Bayer has conducted preclinical studies in AD models showing reduced amyloid burden and improved cognitive function
Merck KGaA / Merck & Co. — sGC Activators
[Merck KGaA](/companies/merck-kgaa) (known as Merck outside the US) and [Merck & Co.](/companies/merck-co) (US) have explored sGC activators for cardiovascular indications.
Mechanism: Direct sGC activation independent of NO
Advantage: Works in oxidative stress conditions where NO signaling is impaired
Status: Preclinical exploration
Notes: May be particularly relevant in AD where NO bioavailability is reduced due to oxidative stress
Pfizer — Vericiguat Development
[Pfizer](/companies/pfizer) collaborated with Merck & Co. to develop vericiguat (Verquvo), an FDA-approved sGC stimulator for heart failure (2021) [@armstrong2020]
Heart Failure Program: Vericiguat — FDA approved 2021 for chronic heart failure
Alzheimer's Disease Potential:
Mechanism: sGC stimulation for neuroprotection
Status: Preclinical/early clinical planning
Rationale: The cardiovascular safety profile is established; repurposing for CNS indications is under consideration
Notes: Pfizer has indicated interest in exploring cardiovascular-cerebral connections in neurodegeneration
AbbVie — NO-cGMP Pathway Modulation
[AbbVie](/companies/abbvie) has interest in nitric oxide signaling modulators for neurodegenerative diseases.
Related Programs:
Nitric oxide synthase (NOS) modulators
cGMP-dependent protein kinase (PKG) activators
Alzheimer's Disease Potential:
Mechanism: Targeting multiple points in the NO-sGC-cGMP axis
Status: Discovery
Notes: AbbVie's neuroscience pipeline includes various approaches to address vascular and metabolic aspects of AD
Roche / Genentech — cGMP Signaling Modulation
[Roche](/companies/roche) and [Genentech](/companies/genentech) have explored cGMP-modulating strategies.
Related Programs:
PDE inhibitors (PDE9, PDE5) — cGMP pathway
Neurotrophic factor signaling
Alzheimer's Disease Potential:
Mechanism: Enhancing cGMP signaling through multiple approaches
Status: Discovery
Notes: Roche's expertise in CNS drug development and biomarkers positions them to pursue novel cGMP-targeted approaches
Research Landscape
Academic and Preclinical Groups
| Institution | Focus Area | Key Research | |-------------|-----------|--------------| | University of Edinburgh | sGC and cerebral blood flow | [@liu2014] | | University of Tubingen | sGC in neurodegeneration | [@stasch2011] | | Johns Hopkins | cGMP and tau pathology | [@thal2018] | | University of Michigan | sGC and neuroinflammation | [@nagai2019] | | King's College London | NO-sGC-cGMP in AD models | [@sullivan2022] |
Clinical Trial Landscape
As of 2026, no sGC modulators have reached late-stage clinical trials for Alzheimer's disease. Early-stage programs include:
Phase 1/2 trials planned for sGC stimulators in AD
Biomarker studies evaluating CSF cGMP levels
Neuroimaging studies of cerebral blood flow
Challenges and Opportunities
Challenges:
Blood-brain barrier penetration of sGC modulators
Optimal dosing for CNS vs. cardiovascular effects
Long-term safety in elderly populations
Biomarker validation for target engagement
Opportunities:
Addressing vascular dysfunction — an undertreated aspect of AD
Combination potential with anti-amyloid and anti-tau therapies
Potential for disease modification through improved cerebral perfusion
Established safety profiles from cardiovascular indications
Pipeline Summary
| Company | Compound | Mechanism | Stage | Indication | |---------|----------|-----------|-------|------------| | Bayer | Riociguat | sGC stimulator | Preclinical | AD | | Merck KGaA | Cinaciguat | sGC activator | Preclinical | AD | | Pfizer/Merck & Co. | Vericiguat | sGC stimulator | Preclinical | AD | | AbbVie | Various | NOS/sGC modulators | Discovery | AD | | Roche/Genentech | Various | cGMP modulation | Discovery | AD |